Abstract
The list of therapeutically relevant biomarkers in NSCLC is continually expanding and hence molecular profiling is of paramount importance. Tissue availability and chance of rebiopsy is a major limitation in lung cancer and sequential single gene assays lead to tissue exhaustion and inadvertent delays in institution of therapy. We sought to compare the performance of targeted next-generation sequencing (NGS) panels with traditional assays and correlate the mutational landscape in an Indian NSCLC cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
